Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure

Digestive Diseases and Sciences

Volumn 58, Issue 5, 2013, Pages 1397-1402

  Singh, Sundeep ^a   Hynan, Linda S ^b   Lee, William M ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Acute liver failure; ALF; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLUCOSE; PARACETAMOL;

ACUTE LIVER FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG OVERDOSE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSPLANTATION;

ACETYLCYSTEINE; ADULT; BIOLOGICAL MARKERS; COMA; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; PROSPECTIVE STUDIES;

EID: 84878682848     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2512-x     Document Type: Article

References (12)

1. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases. New York: Grune & Stratton; 1970:282-298.
2. Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995;21:240-252.
3. Ostapowicz G, Fontanta RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-955.
4. Prescott LF, Critchley JA. The treatment of acetaminophen poisoning. Ann Rev Pharmacol Toxicol. 1983;23:87-101.
5. Hamlyn AN, Douglas AP, James O. The spectrum of paracetamol (acetaminophen) overdose: clinical and epidemiological studies. Postgrad Med J. 1978;54:400-404.
6. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856-864.
7. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852-1857.
8. Walsh TS, Hopton P, Philips BJ, et al. The effect of N-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure. Hepatology. 1998;27:1332-1340.
9. Rank N, Michel C, Haertel C, et al. N-acetylcysteine increases blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med. 2000;28:3799-3807.
10. Chen Y, Johansson E, Yang Y, et al. Oral N-acetylcysteine rescues lethality of hepatocyte-specific GcIc-knockout mice, providing a model for hepatic cirrhosis. J Hepatol. 2010;53:1085-1094.
11. González R, Ferrín G, Hidalgo AB, et al. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact. 2009;181:95-106.
12. Jin X, Wang L, Wu HS, et al. N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int. 2007;6:284-289.